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Using a newly generated monoclonal antibody we
identi®ed the 96 kDa transmembrane receptor SC5
expressed simultaneously on a human Sezary cell
line and a minor T cell subset in normal individuals.
SC5 antigen was detected mostly on CD45RO+ lym-
phocytes from both CD4+ and CD8+ subsets as well
as on natural killer and B lineage cells. SC5 surface
expression increased very early after polyclonal
stimulation of CD3+ cells due to the transfer of
intracellular SC5 molecules to the cell membrane.
Engagement of SC5 receptor by its monoclonal anti-
body inhibited the anti-CD3-induced proliferation
and cytokine secretion of peripheral blood T cells
and cell clones, whereas SC5 monoclonal antibody
did not affect the cytotoxic activity of CD8+ T cell
clones. Extensive phenotypic analysis revealed that
the percentage of SC5+ CD4+ circulating lympho-
cytes in Sezary syndrome patients was signi®cantly
increased in comparison with controls (p < 0.01) and
correlated with the morphologically detected per-
centage of Sezary syndrome cells in peripheral blood
(p <0.001). In one patient we clearly demonstrated
that the circulating malignant T cells coexpress SC5
molecules. Importantly, ligation of SC5 receptor in a
cutaneous T cell lymphoma cell line profoundly
inhibited the anti-CD3-induced proliferation.
Consequently, the expression of SC5 receptor in the
peripheral blood of Sezary syndrome patients may
serve not only to detect the presence of circulating
malignant CD4+ cells but also as a target for immu-
notherapy. Key words: CTCL/ lymphocyte antigen/ lym-
phocyte proliferation inhibition/ Sezary syndrome. J Invest
Dermatol 116:731±738, 2001
T
lymphocyte immune responses are regulated by
functional cell surface molecules providing positive
signals that lead to the expansion of antigen-speci®c
clones, and negative signals that prevent excessive
stimulation or responsiveness to self-antigens. The
signal provided by the engagement of T cell receptors (TCR)
must be accompanied by a second positive signal in order to
result in optimal T cell response. Recent studies demonstrated
that CD3/TCR stimulation leads to a redistribution of the
detergent-insoluble glycolipid-enriched membrane fraction
(DIG) or raft, which results in the aggregation of TCR/CD3
and DIG-associated signal-transducing molecules (Montixi et al,
1998). CD28, which is considered as the major T cell
costimulatory receptor (Watts and DeBenedette, 1999; Yumi
et al, 2000), enhances raft redistribution to the site of TCR
engagement (Viola et al, 1999). Further, a series of other
molecules may provide costimulatory signals to T cells, acting at
different time points, affecting different subsets, or promoting
distinct effector functions (Shuford et al, 1997; Agrawal et al,
1999; Hutloff et al, 1999; Tamada et al, 2000). Negative
regulation of T lymphocyte responses can be mediated by
CD152-induced signals (Thompson and Allison, 1997), by
apoptosis through members of the tumor necrosis factor (TNF)
receptor superfamily (Lenardo et al, 1999), or by the inhibitory
receptors recently discovered on subsets of natural killer cells
and CD8+ T lymphocytes (Mingari et al, 1995, 1998; D'Andrea
et al, 1996).
In this report, we describe a novel 96 kDa transmembrane
receptor, SC5, which delineates a minor subset of peripheral
blood lymphocytes (PBL) in normal individuals. We found
that SC5 was predominantly located in the intracellular
compartment of resting T lymphocytes and its surface mem-
brane expression increased rapidly after cell activation. SC5
molecule engagement inhibited the anti-CD3 monoclonal
antibody (MoAb) induced proliferation of resting T lymphocytes
or T cell clones. Further, we observed that the percentage of
SC5+ CD4+ circulating lymphocytes was signi®cantly increased
in Sezary syndrome (SS) patients compared to PBL of normal
individuals. Importantly, we were able to demonstrate that
Sezary cells express SC5 molecules and that their triggering
resulted in a strong inhibition of a cutaneous T cell lymphoma
(CTCL) cell line proliferation induced by anti-CD3 MoAbs.
Thus, SC5 molecule expression may serve to detect the
presence of circulating malignant CD4+ cells in SS patients.
Moreover, the identi®cation of a cell surface molecule provid-
ing negative signals upon ligation constitutes a new tool to
investigate the mechanisms of pathologic T cell growth and
could be used to prevent it.
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MATERIALS AND METHODS
Production of anti-SC5 MoAb SC5 MoAb was obtained by
immunizing 6-wk-old BALB/C mice with the natural killer cell line
Ytindi, using an established protocol (David et al, 1990). Hybridoma
supernatants were screened for selective reactivity with the immunizing
cell line and a CTCL cell line termed Pno (Poszepczynska et al, 2000)
by indirect immuno¯uorescence and ¯ow cytometry. The reactive
supernatants were further tested on PBL. A hybridoma supernatant
reacting with both tumoral cell lines and with a minor PBL
subpopulation was selected and cloned twice, and cloned hybridomas
were passaged into pristane-primed BALB/C mice to produce ascites.
The antibody was termed anti-SC5 MoAb, and its isotype was
determined as IgM. The ascites was dialyzed against phosphate-buffered
saline (PBS), sterilized by ultra®ltration, and further utilized at a ®nal
dilution of 1:200.
Patients After informed consent and approval by an ethics committee
(CCPPRB, HoÃpital Henri Mondor, Creteil), we obtained blood samples
from 12 patients with CTCL. Nine patients had an SS with 10%±80%
circulating CD3+, CD4+ Sezary cells, whereas three patients had a
transformed mycosis fungoides (MF) and presented with disseminated
skin tumors with a CD3+, CD4+, CD8± phenotype. The patients had
not been previously treated with chemotherapy.
Cells and cell lines Peripheral blood mononuclear cells (PBMC) were
isolated by the technique of Ficoll-Isopaque (Pharmacia, Piscataway, NJ)
density gradient centrifugation. Human T cell clones GDS.3 (CD3+
TCRab+ CD4+ CD8±), DS6 (CD3+ TCRgd+ CD4± CD8±), LSO
(CD3+ TCRgd+ CD4± CD8±), and JF1 (CD3+ TCRab+ CD4±
CD8+), described elsewhere (David et al, 1987, 1988; Vilmer et al,
1988), were fed each 8 d with irradiated allogenic PBMC in culture
medium consisting of RPMI 1640 (Gibco, Paisley, U.K.), 2 mmol per l
L-glutamine, penicillin (100 U per ml), streptomycin (100 mg per ml),
10% heat-inactivated human serum, 50 IU per ml recombinant
interleukin-2 (rIL-2) (kindly provided by Sano® SyntheÂlabo, LabeÁge,
France), and 1 mg per ml phytohemagglutinin (PHA) (Wellcome,
Beckenham, U.K.). Functional studies were performed at day 7 after the
feeding. Standard human leukemic cell lines were mycoplasma-free and
maintained in logarithmic growth in complete RPMI medium
supplemented with 10% fetal bovine serum and antibiotics. The human
CTCL cell clone, Pno, was established from peripheral blood of a CTCL
patient and maintained in culture as previously described (Poszepczynska
et al, 2000). The Pno cell line has a CD3+ Vb22+ CD4+ CD8aa+
CD25± phenotype and proliferates in response to IL-7 and to anti-CD3
MoAb stimulation.
Monoclonal antibodies and ¯ow cytometry studies Indirect
immuno¯uorescent staining was performed with hybridoma supernatants
or ascites ¯uid using ¯uorescein isothiocyanate (FITC) conjugated goat
antimouse Ig from Caltag Laboratories (San Francisco, CA). For two-
color analysis the immuno¯uorescent staining was performed by
incubating 3 3 105 cells with anti-SC5 MoAb for 30 min at 4°C. Cells
were then washed and incubated with FITC-conjugated goat antimouse
IgM (Caltag Laboratories) followed by a second PE-, ECD- or TRI-
conjugated speci®c MoAb of IgG isotype. Stained cells were analyzed
using a single argon ¯ow cytometer analyzer (Epics XL, Beckman-
Coulter, Miami, FL) as described previously (Schiavon et al, 1999). For
intracellular labeling, cells were ®xed in PBS 4% p-formaldehyde for
20 min at 4°C, washed, and then permeabilized with staining buffer
containing 0.1% saponin. Conjugated anti-CD3, anti-CD4, anti-CD8,
anti-CD45RO, anti-CD69, and anti-TCRVb22 MoAbs were purchased
from Immunotech (Marseille, France). Other MoAbs were locally
produced or obtained through the exchanges of the Vth International
Workshop on white cell differentiation antigens (Boston, MA,
November 1994).
Immunoprecipitation of biotinylated surface molecules Two
3 107 cells were washed twice in PBS and surface-labeled with Sulfo-
NHS-LC biotin (Pierce Europe, Interchim, MontlucËon, France), 2 mg
per ml in PBS for 20 min at 4°C. After quenching for 20 min with
RPMI 1640, cells were washed twice in PBS and resuspended in lysis
buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100,
1 mM Na vanadate, 10 mM NaF, 1 mM phenylmethylsulfonyl ¯uoride,
1 mg per ml aprotinin, and 1 mg per ml leupeptin) for 1 h at 4°C.
Postnuclear supernatant was then incubated for 2 h at 4°C in a 96-well
plate (Maxisorp Nunc immunoplate) precoated with goat antimouse
IgG + IgM (Caltag Laboratories) followed by anti-SC5 MoAb or anti-
TCRb (C305 isotype matched MoAb, kindly provided by Dr. A. Weiss,
University of California, San Francisco, CA). Immunoprecipitates were
washed four times with washing buffer (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.1% Triton X-100, 1 mM Na vanadate, 10 mM NaF,
1 mM phenylmethylsulfonyl ¯uoride) and precipitated proteins were
subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE). Western blot analysis was performed using streptavidin-
peroxidase (Immunotech) and the ECL detection system according to
the manufacturer's recommendations (Amersham Pharmacia, Orsay,
France).
Proliferation assays For lymphocyte activation, PBMC were cultured
in culture medium containing 15% human serum in the presence of 1 mg
per ml PHA (Wellcome). For proliferation assays, 5 3 104 cells were
cultured in triplicates in 96-well round-bottomed plates (Greiner,
NuÈrtingen, Germany) in a ®nal volume of 0.2 ml culture medium.
When needed, the plates were precoated with anti-CD3 MoAb in the
indicated dilutions as previously described (Poszcepczynska et al, 2000).
For stimulation of the Pno cell line, precoated anti-CD3 MoAb (2.5 mg
per well) was used in combination with 2 ng per ml phorbol 12b-
myristate 13a-acetate (PMA, Sigma Biochemicals). Cells were cultured
for 4 d and were pulsed with 1 mCi of 3H[TdR] during the last 8±16 h
of culture. 3H[TdR] incorporation was measured in a liquid scintillation
counter (Topcount; Packard Instrument, Meriden, CT) For the
determination of IL-2 production, 105 PBL were stimulated with
immobilized anti-CD3 MoAb in the presence of anti-SC5 or control
MoAb. After 32 h of culture, 100 ml of supernatant was added to 105
cells from an Il-2-dependent T cell clone.
CD3-induced redirected cytotoxicity assays The redirected
cytotoxicity assay was carried out as already described (Le Cleach et al,
2000). The target murine mastocytoma P815 tumor cells were loaded
with 100 ml 51Cr (2.5 mCi per ml) for 90 min at 37°C, washed, and
incubated with anti-CD3 for 15 min at room temperature. Effector cells
were likewise preincubated with anti-SC5 MoAb (1:200 ®nal dilution of
ascites) and added to target cells in the ratio 5:1, in a ®nal volume of
150 ml in 96-well V-bottomed microtiter plates for 4 h. After
centrifugation 100 ml aliquots were counted in a gamma-counter to
determine 51Cr release. The spontaneous release was always less than
20% of the maximum release (target cells with 1% Nonidet P-40). The
percentage of speci®c 51Cr release was calculated as previously described
(David et al, 1987).
Statistical analysis Statistical analysis of the results was performed with
Statistica software version 5.0 (StatSoft, Los Angeles, CA). Signi®cant
differences between SC5 expression in patients and the control group
were evaluated by the Mann±Whitney U test, and data were presented
using boxplots. Correlation between the percentage of SC5+ CD4+ cells
and the percentage of malignant cells in patients' peripheral blood was
evaluated by the Spearman rank order correlations test.
RESULTS
Expression of SC5 molecules on normal resting and
activated peripheral blood cells Monoclonal antibodies
raised against the functional tumor cell line Ytindi were analyzed
for their simultaneous reactivity with the immunizing cells and the
CTCL cell line Pno (Poszcepczynska et al, 2000). The SC5-speci®c
MoAb, of IgM isotype, stained both the tumor cells and a minor
subset of PBL. The SC5 MoAb reactive molecule was expressed by













CD4+ Ly 8 9.4 5.1
CD8+ Ly 8 14.8 5.1
CD56+ Ly 10 19.4 11.4
CD19+ Ly 5 12.5 5.7
Total Mo 5 100 ±
Total Gr 5 45 5.2
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a variable percentage of CD3+ T cells, never exceeding 20% (mean
10.5%, SD 65.6). Both CD4+ and CD8+ lymphocytes were
stained by anti-SC5 MoAb. A subpopulation of peripheral blood
CD56+ natural killer cells was also reactive with anti-SC5 MoAb,
though with more important interindividual variations (mean
19.4%, SD 611.4) (Table I). It should be noted that most SC5+
lymphocytes belonged to the activation/memory pool, over 80% of
the SC5-positive cells coexpressing CD45RO (Fig 1). Table I
further indicates that anti-SC5 MoAb stained a subpopulation of
B cells, practically all monocytes, and 30%±50% of granulocytes.
As SC5 molecule expression was detected in all IL-2-dependent
T lymphocyte clones tested (data not shown), we veri®ed whether
its self-surface expression was induced during T lymphocyte
activation. Stimulation of PBL with PHA promptly increased the
expression of SC5 on CD3+ lymphocytes. Both the percentage of
SC5+ T cells and the level of SC5 expression rose very rapidly after
stimulation (Fig 2 and data not shown). As early as 4 h after
stimulation with PHA, the percentage of SC5+ CD3+ cells
increased 2- to 3-fold and reached a maximum after 24±48 h. In
the course of 5±7 d of in vitro stimulation SC5 expression returned
to the basal level. In parallel we studied the expression of the very
early activation antigen CD69 and we observed similar kinetic
pro®les of CD69 and SC5 on CD3+ lymphocytes. It should be
noted that unlike CD69 molecules low levels of SC5 were already
present on circulating PBL before stimulation (Figs 1, 2).
Activation-induced antigen expression results either from de novo
protein synthesis or cell surface export of preexisting intracellular
molecules. Therefore, we studied the expression of SC5 in
nonactivated permeabilized PBL. As shown in Fig 3, anti-SC5
MoAb stained over 90% of permeabilized lymphocytes versus 16%
of the same nonpermeabilized cells. The speci®city of anti-SC5
MoAb staining was con®rmed by using the isotype-matched MoAb
BY55, which detects a GPI-anchored cell surface structure
expressed by a subset of circulating lymphocytes (Agrawal et al,
1999). A comparable percentage of BY55+ cells was found in
permeabilized and nonpermeabilized lymphocytes. As a positive
control for the detection of an intracellular epitope, we used an
anti-CD3z chain MoAb that only labeled permeabilized T
Figure 1. Cell membrane expression of the
SC5 molecule on PBL from normal
individuals. PBMC from normal individuals
were stained with anti-SC5 MoAb (ascites 1:200)
followed by FITC-conjugated isotype-speci®c
goat antimouse second reagent and one of the
following PE-conjugated MoAbs: anti-CD3, and
anti-CD45RO. The percentage of double-stained
lymphocyte-gated cells is shown in the upper
right quadrant. This experiment is representative
for ®ve donors studied.
Figure 2. Cell membrane expression of the SC5 molecule during
activation of peripheral blood T cells. PBMC were stimulated with
1 mg per ml PHA and the kinetics of SC5 and CD69 expression was
studied in parallel on the CD3+ cells.
Figure 3. Intracellular localization of the SC5 molecule in PBL.
Anti-SC5, anti-CD3z chain MoAb, and anti-BY55 isotype-matched
MoAb were used for staining permeabilized (right) and nonpermeabilized
(left) gated lymphocytes from a normal donor. The shaded histograms
represent the labeling obtained with the indicated MoAb compared to an
irrelevant control MoAb.
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lymphocytes. Thus, the surface expression of SC5 is dynamically
regulated by the activation state of cells and its induction during T
cell activation is due to the enhanced transport of the molecule
from an intracellular pool to the surface membrane.
Biochemical characterization of SC5 antigen In order to
characterize the molecular weight of the structure identi®ed by
anti-SC5 MoAb, an IL-2-dependent TCRgd+ clone, termed DS6
(David et al, 1988), was surface labeled with biotin and the cell
lysates were immunoprecipitated with either anti-SC5 MoAb or an
isotype-matched anti-TCRb MoAb (as negative control). Anti-
SC5 MoAb recognized a single molecule with apparent molecular
weight 96 kDa under reducing conditions (Fig 4). As tumor cell
lines (the immunizing Ytindi cells) are often characterized by
aberrant expression of carbohydrate epitopes (Derappe et al, 1996;
Schiavon et al, 1999), we studied the reactivity of anti-SC5 MoAb
with the SC5+ natural killer cell line NK3.3 after treatment with
neuraminidase or sodium periodate in concentrations destroying
known sialylated epitopes (digestion of CD75 epitope on Raji cells
was used as a positive control). Expression of SC5 was not affected
by neuraminidase or sodium periodate treatment (data not shown).
Thus, we excluded a possible carbohydrate nature of the epitope.
Inhibition of the anti-CD3 MoAb-induced T lymphocyte
proliferation by anti-SC5 MoAb In order to examine the
function of the SC5 molecule in normal T cells, we studied the
effect of anti-SC5 MoAb alone or during the proliferative responses
induced by immobilized anti-CD3 MoAb. We found that anti-SC5
MoAb alone or in combination with PMA did not induce the
proliferation of peripheral blood T lymphocytes (data not shown).
Interestingly, when soluble anti-SC5 MoAb was present together
with immobilized anti-CD3 MoAb, a signi®cant inhibition of
lymphocyte proliferation rate was observed. The inhibition varied
between 33% and 66% at day 4, depending on the donor,
compared to the effect of an isotype-matched irrelevant control
MoAb (data not shown). As SC5 molecules are expressed on
monocytes, it was important to determine whether the inhibitory
effect was monocyte independent. We studied the proliferation of
two T cell clones, GDS.3 and LSO, stimulated by immobilized
anti-CD3 MoAb in the presence of anti-SC5 MoAb or an isotype
control MoAb. The results obtained with both T cell clones
indicated that engagement of SC5 molecules resulted in an
inhibition of the proliferation to anti-CD3 MoAb (Fig 5A). It
should be noted that the inhibitory effect of anti-SC5 MoAb on T
cell proliferation depended on the concentration of the agonistic
anti-CD3 MoAb. The inhibition obtained with anti-SC5 MoAb
was signi®cant only when T cells were stimulated with optimally
Figure 4. Biochemical analysis of SC5 molecule. DS6 T cell clone
was surface labeled with biotin and 1% Triton X-100 lysates were
immunoprecipitated using anti-SC5 MoAb. The samples were analyzed
by SDS-10%-PAGE under reducing conditions. Anti-SC5 MoAb was
used in two concentrations: 1:200 (lane 2) and 1:500 (lane 3). The
negative control samples were precipitated with goat antimouse alone
(lane 1) and isotype-matched irrelevant MoAb (lane 4). The molecular
weight markers (kDa) are indicated on the left.
Figure 5. Anti-SC5 MoAb modulates the anti-CD3-induced proliferation and cytokine secretion of normal T lymphocytes without
affecting their cytotoxic activity. (A) The T cell clones LSO and GDS.3 were stimulated with immobilized anti-CD3 MoAb (1 mg of MoAb
coated per well) or with IL-2 (50 IU per ml) in the presence of anti-SC5 MoAb (1:200 ®nal dilution of ascites) or an isotype-matched irrelevant
MoAb (anti-CD34). Results shown are representative of at least three separate experiments and are expressed as mean cpm 6 SD of triplicate wells. (B)
GDS.3 CD4+ T cell clone was stimulated with the indicated concentrations of precoated anti-CD3 MoAb in the presence of anti-SC5 MoAb or
isotype-matched irrelevant MoAb. (C) IL-2 secretion in the supernatant of anti-CD3-stimulated PBL, in the presence of anti-SC5 or control MoAb,
was assessed by measuring the proliferation of an IL-2-dependent T cell clone in the presence of: medium alone (a), supernatant from PBL/anti-CD3+
control MoAb (b), supernatant from PBL/anti-CD3+ anti-SC5 MoAb (c). The data represent the mean values 6 SD of triplicate determinations of one
out of three representative experiments. (D) JF1, a cytotoxic CD8+ cell clone, was incubated with anti-SC5 MoAb (1:200 ®nal dilution of ascites) or
with an isotype-matched control MoAb (anti-CD34) before coculture with the FcgR+ murine tumor cells P815 at an E:T ratio of 5:1. Target cells
were preincubated with the indicated ®nal concentrations of anti-CD3 MoAb. Results are expressed as the mean of triplicate wells.
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diluted anti-CD3 MoAb (Fig 5B). Such inhibitory behavior was
also reported for anti-killer cell immunoglobulin receptor (anti-
KIR) MoAbs (Cambiaggi et al, 1999).
The decrease of T cell proliferation following SC5 engagement
could be due to a direct induction of cell death, a perturbation of
the IL-2R expression, or the inhibition of cytokine synthesis. We
found that anti-SC5 MoAb did not inhibit the IL-2-dependent
proliferation of T cell clones (Fig 5A). Furthermore, the addition
of rIL-2 to T cells preincubated with anti-SC5 MoAb (ascites
diluted to 1:200) in combination with anti-CD3 for 48 h restored
their proliferation rate. This would not be the case if the speci®c
MoAb inhibited IL-2R expression or caused cell death (data not
shown). Finally, in order to prove that SC5 triggering may inhibit
cytokine production, we compared the amount of IL-2 secreted by
anti-CD3-activated PBL in the presence or absence of anti-SC5
MoAb, using an IL-2-dependent T cell line. The quantity of IL-2
produced in the presence of anti-SC5 MoAb represented 40%±65%
of the control values obtained with an isotype-matched antibody
(Fig 5C). Thus, the simultaneous engagement of SC5 and CD3
molecules in T cells results in the decrease in cytokine production.
We next studied the effect of anti-SC5 MoAb on T cell effector
cytotoxic activity using an anti-CD3 MoAb redirected killing assay
against the FcgR+ murine cell line P815. Figure 5(D) shows a
representative experiment performed with a cytotoxic T cell clone
at an E:T ratio of 5:1. The CD8+ T cell clone JF1, expressing a
high amount of SC5 molecules, was induced to kill murine target
cells following anti-CD3 MoAb stimulation. The simultaneous
targeting of SC5 by its speci®c MoAb did not in¯uence JF1
cytotoxic activity, regardless of the E:T ratio (data not shown) or
the concentration of stimulating anti-CD3 MoAb.
Expression of SC5 molecules on malignant lymphocytes
obtained from patients with SS As we initially screened anti-
SC5 MoAb for its reactivity with the Pno CTCL cell line, we
further studied the expression of SC5 molecules in PBL isolated
from nine patients with SS. Two-color ¯ow cytometry analysis
showed that expression of SC5 was increased in the CD4+ subset
(see representative results obtained with one patient in Fig 6A).
The percentage of CD4+ SC5+ lymphocytes in SS patients' blood
was signi®cantly higher compared to healthy controls (p = 0.0015).
As shown in Fig 6(B) practically no overlap existed between the
values observed for the SC5/CD4 population in the patients' group
(median 32%, range 16%±83%) and in the control group (median
11%, range 3%±12%). In the nine SS patients studied, the
expression of SC5 on CD4+ cells correlated with the percentage
of circulating malignant cells detected by cytomorphology
(r = 0.92, p = 0.0012) (Fig 6C). We also studied SC5 molecule
expression in peripheral blood samples from three MF patients
without blood involvement. No signi®cant difference in the levels
of SC5 expression on peripheral blood CD4+ cells was observed
between MF patients and healthy donors. In one SS patient we had
previously demonstrated that the circulating malignant cells were
clonal lymphocytes with a CD4+ TCRVb22+ phenotype
(Poszepczynska et al, 2000). Here we demonstrated that SC5 was
coexpressed by the TCRVb22+ cells, i.e., by the malignant cell
population (Fig 7A). It should be noted that the pro®le of SC5
MoAb binding to TCRVb22+ cells corresponded to a weak
homogeneous expression by the whole malignant clonal cell
population (Fig 7B). Both the circulating malignant cells and the
derived IL-7-dependent TCRVb22 Pno cell line exhibited a
similar pro®le upon staining with anti-SC5 MoAb (data not
shown). Interestingly, the malignant TCRVb22+ cells did not
coexpress common activation markers such as CD69 (Fig 7C),
CD25, or CD30 (Poszepczynska et al, 2000). Thus, the increased
levels of SC5 in SS PBL were mostly due to the expression of the
antigen on circulating malignant T cells.
Inhibition of the anti-CD3 MoAb-induced CTCL cell line
proliferation by anti-SC5 MoAb We next investigated
whether SC5 molecules were able to provide a negative signal in
malignant CTCL cells. We used the long-term cultured Pno
CTCL tumor T cell line, which strongly proliferates in the
presence of IL-7. As previously reported, the Pno cell line expresses
functional T cell receptors, as immobilized anti-CD3 MoAb or the
combination of soluble anti-CD3 MoAb and PMA signi®cantly
induced its proliferation (Poszepczynska et al, 2000). We examined
the effect of SC5 molecule engagement on the proliferation of Pno
cells. Figure 8 shows that anti-SC5 MoAb strongly inhibited the
anti-CD3 MoAb-induced proliferation of the CTCL cell line. In
contrast, PMA alone (2 ng per ml) produced a low level of
proliferation, which was not signi®cantly affected by anti-SC5.
Notably, anti-SC5 MoAb had no effect on the IL-7-dependent
proliferation, as Pno cells incubated with IL-7 in the presence of
anti-SC5 MoAb proliferated as vigorously as in the presence of the
isotype control MoAb. Thus, we concluded that SC5 antigen is
functional in a CTCL malignant cell line and may speci®cally and
profoundly inhibit its proliferation triggered through the TCR/
CD3 signaling pathway.
DISCUSSION
A number of receptors with dynamic surface expression can
modulate T cell immune responses. In this study, we identi®ed a
novel 96 kDa functional molecule expressed by a minor subset of
PBL whose surface expression is induced rapidly during in vitro T
cell activation. SC5 is distinct from the established molecules with
similar molecular weight and/or T cell modulatory functions. First,
SC5 surface expression was induced after 4 h of T cell activation. A
similar kinetics has been observed for the very early activation
antigen CD69 (Resti et al, 1994). Most established T-cell-speci®c
inducible receptors such as 4-1BB (Shuford et al, 1997), OX-40
(Watts et al, 1999), LIGHT (Tamada et al, 2000), or CD152
(CTLA-4) (Thompson and Allison, 1997) appear on the T cell
surface between 10 and 24 h following stimulation. Further, SC5
expression is not T cell restricted. The antigen was detected on
subpopulations of natural killer and B lymphocytes, monocytes, and
granulocytes. Such a wide distribution pattern is typical of certain
KIR (Cantoni et al, 1999; Falco et al, 1999) and immunoglobulin-
like transcript inhibitory receptors (Colonna et al, 1998; Lopez-
Botet and Bellon, 1999). Most of these receptors do not depend on
the activation status of cells, however.
The prompt induction of SC5 molecules at the surface of
activated T cells followed by their downregulation may result from
traf®cking of intracellular molecules to the cell membrane and vice
versa, as we detected SC5 in most nonactivated T lymphocytes
after cell permeabilization. Such a cellular localization, which is
modi®ed upon activation, has already been reported for CD152
(Linsley et al, 1996) and a heterogeneous family of lysosome
associated membrane proteins (Goyert, 1997). Additional studies
on the intracellular localization and traf®cking of SC5 would de®ne
its proper role in T cell activation and functions.
Our studies revealed that triggering of SC5 by its speci®c MoAb
inhibited the anti-CD3 MoAb-induced T cell proliferation. This
inhibitory effect required an optimal anti-CD3 MoAb stimulation,
which is necessary to induce maximal SC5 surface expression in
PBL. At the same time, the inhibitory threshold posed by SC5
engagement could be bypassed by excessive anti-CD3 MoAb
stimulation. Recently, the negative regulation of immune responses
has been extensively investigated, in particular in T lymphocytes
and natural killer cells. The best studied T-cell-speci®c inhibitory
receptor, CD152 (CTLA-4), is a typical activation-induced
antigen, functionally coupled to CD28 costimulatory receptor.
Indeed, CD152 may overcome CD28-positive signals at low
antigenic concentrations and prevent immune response.
Alternatively, it may downregulate and terminate T cell prolifer-
ation induced through CD28 by affecting IL-2R expression and
IL-2 synthesis (Krummel and Allison, 1996; Thompson and
Allison, 1997). Similarly to CTLA-4, SC5 is an intracellular
molecule whose surface expression is regulated by the activation
status of cells. Both receptors mediate their effects by affecting IL-2
synthesis. The identi®cation of SC5-speci®c ligands and signaling
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pathways will de®ne the temporal and spatial correlation between
these negative T cell regulators.
In several aspects, SC5 is comparable to KIR, equally expressed
by T cells and other lymphocyte subpopulations.These receptors
were shown to inhibit the antigen-speci®c and superantigen-driven
activation of T cells, including cytotoxicity, proliferation, and
cytokine secretion (Mingari et al, 1995; 1998; D'Andrea et al,
1996). SC5 is de®nitely distinct from KIR, however, as we
demonstrated that it selectively inhibited the proliferation of anti-
CD3 MoAb-stimulated T cells without affecting their effector
cytotoxic functions.
An important characteristic of the SC5 molecule is its signi®-
cantly increased expression in PBL of patients with SS in
comparison to healthy subjects. SS is characterized by the
generalization of a primary epidermotropic malignant T cell
clone with mature phenotype (Bagot et al, 1998). Actually, none
of the established T cell functional receptors conclusively identi®es
peripheral blood SS tumor cells. MF/SS has been considered as the
expansion of a normally existing CD4+ CD7± T cell memory
subset (Reinhold et al, 1993; Reinhold and Abken, 1997).
Interestingly, signi®cantly higher CD4+ CD7± cell counts were
reported in patients with advanced CTCL compared to patients
with early CTCL, and these counts correlated with the detection of
clonality (Laetsch et al, 2000). Another study demonstrated that the
CD4+ CD7± population does not directly represent the dominant
T cell clone in SS patients, however, as clonal cells can be detected
in the CD4+ CD7+ population as well (Dummer et al, 1999).
Established activation antigens such as CD69, CD25, and CD30
are not consistently detected on Sezary cells, as con®rmed by our
own investigations. Expression of CD25 correlates instead with the
progression of the disease and the transformation of MF/SS cells
into a large cell variant in a minority of cases (Diamandidou et al,
Figure 7. SC5 surface membrane expression
on malignant cells from an SS patient. (A)
Two-color immuno¯uorescence analysis of
PBMC from an SS patient with a circulating
TCRVb22+ malignant T cell clone
(Poszcepczynska et al, 2000). Cells were stained
with anti-SC5 MoAb followed by PE-conjugated
isotype-speci®c goat antimouse and FITC-
conjugated anti-TCRVb22 MoAb. (B) Anti-SC5
MoAb weakly labeled (shaded histogram) the
TCRVb22-positive malignant cells. (C) Cells
from the same patient stained with PE-conjugated
anti-CD69 MoAb and FITC-conjugated anti-
TCRVb22 MoAb.
Figure 6. Cell membrane expression of the
SC5 molecule on PBL from CTCL patients.
Cells from peripheral blood of nine patients with
SS and nine healthy donors were analyzed by
two-color ¯uorescence for the expression of SC5
molecule by CD4+ lymphocytes. (A)
Coexpression of SC5 and CD4 molecules in PBL
from a patient with SS in comparison to a normal
individual. (B) Plots representing the expression of
SC5 on CD4+ cells in the two indicated groups.
The ``box'' indicates the 25th to 75th percentile
range, the median value is designated inside, and
the whiskers specify the min and max values
observed. (C) Correlation between the percentage
of SC5+ CD4+ cells and the percentage of
malignant cells in SS patients' peripheral blood.
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1998; Stefanato et al, 1998). An increased rate of expression of T
cell activation molecules such as HLA-DR, CD25, or CD71 in SS
has been primarily associated with reactive tumor-in®ltrating T
cells (Wood et al, 1982; Wieczorek et al, 1986; Asadullah et al,
1997). A 78 kDa very late activation antigen, BE2, was reported to
be speci®cally increased in SS peripheral blood, but not detected on
normal T cells (Berger et al, 1982). In fact, BE2 was not consistently
detected in all SS patients studied, and BE2 was equally detected in
patients without clinical evidence of blood involvement. In
contrast, SC5 was detected in nine of nine SS cases studied.
Although the percentage of malignant cells determined by
cytomorphology varied considerably from patient to patient
(10%±80%), the expression of SC5 on CD4+ cells correlated
with this percentage. Finally, no elevated expression of SC5 was
detected on circulating CD4+ cells from MF patients without
blood involvement or from atopic dermatitis patients (data not
shown). Further, we demonstrated that Sezary cells identi®ed by
the expression of the clonotypic TCRVb chain coexpressed SC5
molecules, con®rming that increased levels of SC5 in the peripheral
blood of SS patients were due to its expression on the malignant T
cell clone.
A very important observation was that SC5 expression on Sezary
cells induced a downmodulation of the CD3-mediated prolifer-
ation of tumor cells, analogous to the inhibition observed in normal
T cells. It has already been demonstrated that malignant CTCL
lymphocytes preserve certain functional properties as they may be
activated through basic signaling pathways, although producing
aberrant pro®les of cytokines (Bagot et al, 1998; Poszepczynska et al,
2000). We now demonstrate that an inhibitory pathway is
preserved in CTCL tumor cells that may allow their proliferation
to be counterbalanced. Notably, the inhibitory effect observed after
anti-SC5 MoAb binding on anti-CD3 MoAb-stimulated CTCL
Pno cells was much more important than in normal T cells. Anti-
SC5 MoAb does not seem to directly mediate cell death of either
normal or Sezary T cells, as it does not modulate the rIL-2-induced
proliferation. Moreover, T cells cultivated in the presence of anti-
SC5 MoAb can be restimulated by addition of rIL-2. At the same
time, we observed a diminished IL-2 production by anti-SC5
MoAb-treated T cells, which should account at least partially for
the inhibition of their proliferation.
Leukocyte functional receptors with inhibitory effects on
malignant cells have already been described. Recently, Moretta et
al reported inhibition of the proliferation of normal and leukemic
myeloid cells mediated by the CD33 myeloid-speci®c antigen and
the homologous natural killer cell sialoadhesin receptor AIRMI
(Vitale et al, 1999). Unlike SC5, these receptors inhibited
proliferation in the presence of growth factors and most probably
by induction of apoptosis. Interestingly, another T cell activation
antigen, CD30, expressed by a subset of normal CD45RO+ T
cells, is likely to mediate the regression of primary CTCL other
than MF/SS. This effect is related to the natural ligand of CD30
(CD30L) that is colocated within the cytoplasm of malignant cells
and may induce cytolytic cell death independently of the Fas/FasL
system (Mori et al, 1999). In this aspect, the identi®cation of SC5
ligand will enlighten the mechanism of its own inhibitory action.
In conclusion, we have identi®ed an early activation antigen that
is distinct, by phenotypic, biochemical, and functional criteria,
from the established T lymphocyte receptors. As has been
emphasized, the SC5 molecule is expressed by a subpopulation of
the postactivation/memory peripheral blood T cell subset.
Likewise, continuous expression of KIR is detected on minor T
cell clones, and this expression seems to depend on TCR
occupancy by speci®c antigens. It was recently proposed that
such clones might be autoreactive and maintained tolerant by KIR
signaling (Huard and Karlsson, 2000). We may speculate that SC5
surface expression is also preserved on auto-reactive T cells,
suggesting that SS tumor cells might originate from such clones.
Importantly, the expression of SC5 on CTCL malignant cells will
serve to better de®ne their origin and the nature of the signal
driving mature T cells to uncontrolled proliferation. In addition,
the inhibitory effect of anti-SC5 MoAb on tumor T cells could
constitute a novel therapeutic approach for patients with advanced
CTCL.
NOTE ADDED IN PROOF
While this manuscript was submitted, Saverino et al, J Immunol
165:3742±3755, 2000, revealed that the inhibitory receptor CD85/
ILT2 was present in the cytoplasm of all human T lymphocytes and
its surface expression was increased upon activation. We performed
phenotypic and biochemical comparison between SC5 and CD85/
ILT2 molecules using speci®c MoAbs. The results clearly demon-
strated that these molecules are different.
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